Exam 1 - GLP­1 Agonists (Incretin­ mimetics)

Question 1

What are the characteristics of the GLP­1 Agonists (Incretin ­mimetics)?

Answer 1

● Not hypoglycemic agents
● MOA: Enhance secretion of insulin in the presence of glucose
● Slow the rate of absorption of glucose and other nutrients by delaying gastric emptying
● Reduce appetite ( increase satiety )
● Inhibit glucagon release (reduces hepatic glucose output)
● Stimulates beta cell differentiation and proliferation?
● These GLP­1 agonists and incretins are deactivated by the enzyme dipeptidyl peptidase 4 (DPP­4). Dulaglutide is less susceptible to inactivation by DPP­4

Question 2

Which are the GLP­1 Agonists (Incretin­ mimetics) drugs?

Answer 2

Exenatide ( Byetta ) (S.C. injection)

Extended release formulation used once weekly = Bydureon®

Liraglutide (Victoza) (S.C. injection)

Albiglutide (Tanzeum, Eperzam) (S.C. injection)

Dulaglutide (Trulicity) (S.C. injection)

Question 3

What are the characteristics of Exenatide, Liraglutide, Albiglutide, Dulaglutide?

Answer 3

● Cause mild weight loss
● Not 1st line
● S.E. = Nausea , vomiting, diarrhea
● Acute pancreatitis ( rare )

Question 4

What do the GLP­1 Agonists (Incretin­ mimetics) drugs end in?

Answer 4

glutide

Question 5

What is the half life of Exenatide?

Answer 5

2.4 hr

Question 6

What is the half life of Liraglutide?

Answer 6

13 hr

Question 7

What is the half life of Albiglutide?

Answer 7

5 days

Question 8

What is the half life of Dulaglutide?

Answer 8

5 days

Question 9

What side effects are specific to Liraglutide and Extended Release Exenatide?

Answer 9

Thyroid C­cell carcinomas/thyroid C­cell hyperplasia in rats

Question 10

What side effects are specific to Exenatide?

Answer 10

Renal insufficiency